Advanced Hybrid Closed-Loop Systems in Perioperative Care: Safety During Anesthesia
Authors' conclusion
During the perioperative period, continuing insulin infusion using AHCL system is feasible, maintaining high levels of %TIR and %TINR, without hypoglycemia or serious adverse events. Randomized clinical trials are needed to compare the use of this technology with usual care.
Study context
- Population
- Adults with T1D or T2D treated with advanced hybrid closed-loop (AHCL) system (MiniMed 780G) undergoing surgical procedures; 86% T1D; age 55.4 ± 16.3 years; 17 procedures (70% elective)
- Participants
- 15 adults17 surgical procedures
- Exposure
- Intraoperative and postoperative periods vs baseline (24 h before admission) in patients using AHCL
- Outcome
- %TIR 70–180 mg/dL
- Follow-up
- Intraoperative
Methodological detailsanalytical study
- Analytical study
Main finding
As reported in the abstract
P < 0.001
Observational data: associations, not effects.
Further findings
%TBR <70 mg/dL · intraoperative · decreased
P < 0.001
%TAR >180 mg/dL · intraoperative · decreased
P < 0.001
- %TINR 70–140 mg/dL at baseline
- 58.6 · ± 22.9 · %
Safety
Hypoglycaemia and device-related adverse events · intraoperative and immediate postoperative
- Hypoglycemic events <70 mg/dL or <54 mg/dL
- 0
- Severe adverse events related to device use
- 0
Original publication
Advanced Hybrid Closed-Loop Systems in Perioperative Care: Safety During Anesthesia. Diabetes Technol Ther. Published 26 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →